Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis.

Meridor, Katya; Sagy, Iftach; Molad, Yair

Meridor, Katya; Sagy, Iftach; Molad, Yair.

Affiliation

Meridor K; Department of Internal Medicine B, Meir Medical Center, Kfar Saba, Israel.
Sagy I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Molad Y; Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.

Mod Rheumatol ; 32(6): 1086-1093, 2022 Oct 15.

Article in En | MEDLINE | ID: mdl-34927207

Subject(s)

Scleroderma, Diffuse; Scleroderma, Systemic; Sjogren's Syndrome; Female; Humans; Lung; Male; Middle Aged; Retrospective Studies; Scleroderma, Diffuse/complications; Scleroderma, Systemic/complications; Scleroderma, Systemic/diagnosis

Key words

Anti-Ro/SS-A antibody; forced vital capacity (FVC); interstitial lung disease (ILD); survival; systemic sclerosis (scleroderma)

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Sjogren's Syndrome / Scleroderma, Diffuse Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Mod Rheumatol Year: 2022 Type: Article Affiliation country: Israel

Fulltext

XML

PubMed Links

Search on Google